An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency

Trial Profile

An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs AG 348 (Primary)
  • Indications Inborn error pyruvate metabolism disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTIVATE-T
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 17 Jun 2018 Trial design of the study presented at the 23rd Congress of the European Haematology Association.
    • 04 May 2018 Status changed from planning to recruiting.
    • 11 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top